Travere Therapeutics, Inc.
TVTX
$62.12
$0.691.12%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 48.17% | 55.63% | 73.41% | 162.11% | 111.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 48.17% | 55.63% | 73.41% | 162.11% | 111.49% |
| Cost of Revenue | 7.75% | 31.05% | -6.49% | 0.32% | 14.41% |
| Gross Profit | 100.41% | 144.31% | 581.28% | 1,061.10% | 2,294.77% |
| SG&A Expenses | 53.58% | 32.84% | 46.32% | 31.75% | -3.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.32% | 31.92% | 20.87% | 17.66% | 4.90% |
| Operating Income | 131.26% | 13.50% | 45.35% | 144.50% | 81.13% |
| Income Before Tax | -174.84% | 10.84% | 65.09% | 146.89% | 81.69% |
| Income Tax Expenses | -1,120.00% | -407.69% | 1,379.17% | 109.52% | -76.47% |
| Earnings from Continuing Operations | -172.81% | 11.22% | 63.52% | 146.95% | 81.69% |
| Earnings from Discontinued Operations | -- | -- | 617,775.00% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -172.81% | 10.00% | 104.53% | 146.90% | 81.88% |
| EBIT | 131.26% | 13.50% | 45.35% | 144.50% | 81.13% |
| EBITDA | 499.41% | 60.82% | 69.75% | 190.92% | 102.41% |
| EPS Basic | -159.55% | 13.44% | 104.16% | 140.88% | 84.22% |
| Normalized Basic EPS | -161.45% | 14.25% | 67.10% | 140.97% | 83.90% |
| EPS Diluted | -159.55% | 13.44% | 104.16% | 139.08% | 84.22% |
| Normalized Diluted EPS | -161.45% | 14.25% | 67.10% | 135.62% | 83.90% |
| Average Basic Shares Outstanding | 5.10% | 3.98% | 8.65% | 14.72% | 14.77% |
| Average Diluted Shares Outstanding | 5.10% | 3.98% | 8.65% | 31.94% | 14.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |